The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
- 1 August 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (15) , 4637s-4640s
- https://doi.org/10.1158/1078-0432.ccr-07-0653
Abstract
The phosphoinositide 3-kinase signaling network is widely implicated in the pathogenesis of human cancer. This pathway is commandeered by cancer cells to promote unrestrained cellular growth and survival. In this brief review, we speculate about the uses of inhibitors of phosphoinositide 3-kinase signaling as treatments for human cancers, with an emphasis on non–small cell lung cancer.Keywords
This publication has 25 references indexed in Scilit:
- PIK3CA mutation status in Japanese lung cancer patientsLung Cancer, 2006
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJournal of Clinical Investigation, 2006
- Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancerOncogene, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signallingBiochemical Society Transactions, 2003
- Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene, 2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.Endocrine-Related Cancer, 2001
- DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinomaGenes, Chromosomes and Cancer, 1998
- SH2 domains recognize specific phosphopeptide sequencesPublished by Elsevier ,1993